Documented concern based on cited evidence — not a personalized safety check, not medical advice, and not a decision to combine or avoid. That decision belongs with your prescriber.

Documented concern — monitor and disclose

Clinically relevant documented concern. Disclose the supplement to your clinician and keep monitoring in place.

Mechanism and evidence

Same NO-cGMP pathway as citrulline; meta-analyses show the combination has been studied under supervision, but self-directed stacking carries additive hypotension risk.

Evidence tier: meta

The tier names the strongest cited study design. Some anchors studied the supplement on its own, or a related drug in the same class — in those pairs the grade rests on that evidence plus established pharmacology, as agreed with our medical reviewer.

What to discuss with your prescriber

  • Same rule as citrulline: prescriber approval first, blood pressure monitoring during use.
  • Report dizziness from a blood-pressure drop or near-fainting.

← All reviewed pairs for PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil)